Jorge E. Vidal, PhD

Assistant Professor

Hubert Department of Global Health, Rollins School of Public Health

Visiting Researcher, Respiratory Pathogens Branch

Centers for Disease Control and Prevention (CDC), Atlanta, GA

Associate Faculty Member

program in Population Biology Ecology and Evolution (PBEE), Graduate Division of Biological and Biomedical Sciences (GDBBS), Emory University

Associate Faculty Member

Graduate Program in Medical Sciences, University of Sinaloa School of Medicine. Sinaloa Mexico

Faculty Member

Center for Childhood Infections and Vaccines (CCIV), Emory+Children's Pediatric Research Center, Children's Healthcare of Atlanta

Phone: 404-3-712-8675


Research Interests

My laboratory is focused on explaining how bacterial respiratory and meningeal pathogens, including Streptococcus pneumoniae, colonize, persist, begin virulence and acquire resistance to antibiotics. We are equipped with cutting edge technology to evaluate antibiotic resistance, identify and type pneumococcal strains and study genetics of antibiotic resistance. Our ultimate goal is to contribute on finding preventive and therapeutic approaches against bacterial diseases such as otitis media, sinusitis, and pneumonia. Studies in my laboratory are currently evaluating antibiotic treatment regimens to maximize the rate of microbiological cure of pneumococcal sinusitis and pneumonia. We are also exploring changes in antibiotic resistance profiles of pneumococcal strains after the worldwide introduction of pneumococcal vaccines. Given the importance of resistance for human pneumococcal disease, we have designed an in vitro system (biBio) that simulates the upper and lower human airways to recreate human infection. Using biBio we are testing resistance to antimicrobials, on a more natural environment, during carriage of respiratory pathogens or infection of human respiratory cells. My laboratory is also involved in two phase III clinical trials with Cempra pharmaceutical, Inc. where we are assisting on evaluating the efficacy of a new antibiotic (Solithromycin) to treat community acquired bacterial pneumonia (CABP). Our research interest also include mechanism(s) of transference or acquisition of antibiotic resistance determinants as well as acquisition and modification of capsular genes. These mechanisms generate resistant strains with new/different capsular types that pose a risk for both treatment and vaccine failures.